Development and pharmacokinetic evaluation of chewable doxycycline tablets in Beagle dogs: comparison with a commercial formulation and evaluation of co-administration with vitamin supplement on the bioavailability
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Veterinary Medicine |
Texto Completo: | https://rbmv.org/BJVM/article/view/1194 |
Resumo: | Doxycycline (DOX) is the antibiotic of choice for the treatment of canine monocytic ehrlichiosis (CME), one of the main infectious diseases affecting dogs. Despite the therapeutic simplicity, the need for long-term use of DOX tablets (28 days) and gastrointestinal effects may pose problems. The aim of the study was to develop a DOX chewable tablet, evaluate its palatability and pharmacokinetic profile in comparison with a commercial formulation, Doxifin®, and evaluate the influence of co-administration with vitamin supplement on the bioavailability of doxycycline. The AUC0-t values found for DOX chewable tablets (13.85 ± 3.81 μg.h/mL) and Doxifin® (15.88 ± 4.38 μg.h/mL) did not differ significantly (p<0.05). The co-administration of the vitamin supplement Hemolitan® influenced the pharmacokinetic profile of DOX, leading to a decrease in bioavailability for chewable DOX tablets and Doxifin®, with relative bioavailability values (F) of 64% and 62%, respectively. Palatability evaluations confirmed the palatability of the chewable tablets. Therefore, a DOX chewable tablet is an important alternative that can overcome some of the challenges associated with the characteristic bitter taste of doxycycline, with considerable reduction animal stress, and with plasma doxycycline concentrations equivalent in practical terms to a conventional product. |
id |
SBMV-1_4e0411b889553ff8f62ff4f9c8dc4f71 |
---|---|
oai_identifier_str |
oai:ojs.rbmv.org:article/1194 |
network_acronym_str |
SBMV-1 |
network_name_str |
Brazilian Journal of Veterinary Medicine |
repository_id_str |
|
spelling |
Development and pharmacokinetic evaluation of chewable doxycycline tablets in Beagle dogs: comparison with a commercial formulation and evaluation of co-administration with vitamin supplement on the bioavailabilityDesenvolvimento e avaliação farmacocinética de comprimidos mastigáveis de doxiciclina em cães Beagle: comparação com uma formulação comercial e avaliação da coadministração com suplemento vitamínico na biodisponibilidadedoxicilina, comprimidos mastigáveis, palatabilidade, farmacocinética.doxycycline, chewable tablets, palatability, pharmacokinetic.Doxycycline (DOX) is the antibiotic of choice for the treatment of canine monocytic ehrlichiosis (CME), one of the main infectious diseases affecting dogs. Despite the therapeutic simplicity, the need for long-term use of DOX tablets (28 days) and gastrointestinal effects may pose problems. The aim of the study was to develop a DOX chewable tablet, evaluate its palatability and pharmacokinetic profile in comparison with a commercial formulation, Doxifin®, and evaluate the influence of co-administration with vitamin supplement on the bioavailability of doxycycline. The AUC0-t values found for DOX chewable tablets (13.85 ± 3.81 μg.h/mL) and Doxifin® (15.88 ± 4.38 μg.h/mL) did not differ significantly (p<0.05). The co-administration of the vitamin supplement Hemolitan® influenced the pharmacokinetic profile of DOX, leading to a decrease in bioavailability for chewable DOX tablets and Doxifin®, with relative bioavailability values (F) of 64% and 62%, respectively. Palatability evaluations confirmed the palatability of the chewable tablets. Therefore, a DOX chewable tablet is an important alternative that can overcome some of the challenges associated with the characteristic bitter taste of doxycycline, with considerable reduction animal stress, and with plasma doxycycline concentrations equivalent in practical terms to a conventional product.A doxiciclina (DOX) é o antibiótico escolhido para o tratamento da erliquiose monocítica canina (EMC), uma das principais doenças infecciosas que afetam os cães. Apesar da simplicidade terapêutica, a necessidade do uso prolongado de comprimidos de DOX (28 dias) e os efeitos gastrointestinais podem representar problemas. O objetivo do estudo foi desenvolver um comprimido para mastigar de DOX, avaliar sua palatabilidade e perfil farmacocinético em comparação com uma formulação comercial, Doxifin®, e avaliar a influência da coadministração com suplemento vitamínico na biodisponibilidade da doxiciclina. Os valores de AUC0-t encontrados para comprimidos mastigáveis de DOX (13,85 ± 3,81 μg.h/mL) e Doxifin® (15,88 ± 4,38 μg.h/mL) não diferiram significativamente (p<0,05). A coadministração do suplemento vitamínico Hemolitan® influenciou o perfil farmacocinético, levando a uma diminuição da biodisponibilidade para comprimidos mastigáveis de DOX e Doxifin®, com valores de biodisponibilidade relativa (F) de 64% e 62%, respectivamente. As avaliações da palatabilidade confirmaram que os comprimidos mastigáveis são palatáveis. Portanto, um comprimido para mastigar de DOX é uma alternativa importante que pode superar alguns dos desafios associados ao sabor amargo característico da doxiciclina, com considerável redução do estresse animal e com concentrações plasmáticas de doxiciclina equivalentes em termos práticos a um produto convencional.Sociedade de Medicina Veterinária do Estado do Rio de Janeiro.2021-09-28info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionpeer reviewedAvaliado pelos paresapplication/pdftext/xmlhttps://rbmv.org/BJVM/article/view/119410.29374/2527-2179.bjvm002921Brazilian Journal of Veterinary Medicine; Vol. 43 No. 1 (2021); e002921Revista Brasileira de Medicina Veterinária; v. 43 n. 1 (2021); e0029212527-21790100-2430reponame:Brazilian Journal of Veterinary Medicineinstname:Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ)instacron:SBMVenghttps://rbmv.org/BJVM/article/view/1194/1096https://rbmv.org/BJVM/article/view/1194/1216Copyright (c) 2021 Isabela de Paula Lima, Viviane de Souza Magalhães, Rodrigo Machado de Oliveira, Thais Paes Ferreira, Gabriela Carmelinda Martins dos Santos, Melina Cardilo Campos Alves, Geraldo Augusto Pereira, Fernanda Cristina Santos da Silva, Liliane Ferreira Rodrigues, Debora Azevedo Borges, Priscila Cardim de Oliveira, Fabio Barbour Scott, Yara `Peluso Cidhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessLima, Isabela de PaulaMagalhães, Viviane de Souzade Oliveira, Rodrigo MachadoFerreira, Thais Paesdos Santos, Gabriela Carmelinda MartinsAlves, Melina Cardilo CamposPereira, Geraldo Augustoda Silva, Fernanda Cristina SantosRodrigues, Liliane FerreiraBorges, Debora Azevedode Oliveira, Priscila CardimScott, Fabio BarbourCid, Yara `Peluso2022-06-27T12:15:40Zoai:ojs.rbmv.org:article/1194Revistahttps://rbmv.org/BJVMONGhttps://rbmv.org/BJVM/oaicontato.rbmv@gmail.com2527-21790100-2430opendoar:2022-06-27T12:15:40Brazilian Journal of Veterinary Medicine - Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ)false |
dc.title.none.fl_str_mv |
Development and pharmacokinetic evaluation of chewable doxycycline tablets in Beagle dogs: comparison with a commercial formulation and evaluation of co-administration with vitamin supplement on the bioavailability Desenvolvimento e avaliação farmacocinética de comprimidos mastigáveis de doxiciclina em cães Beagle: comparação com uma formulação comercial e avaliação da coadministração com suplemento vitamínico na biodisponibilidade |
title |
Development and pharmacokinetic evaluation of chewable doxycycline tablets in Beagle dogs: comparison with a commercial formulation and evaluation of co-administration with vitamin supplement on the bioavailability |
spellingShingle |
Development and pharmacokinetic evaluation of chewable doxycycline tablets in Beagle dogs: comparison with a commercial formulation and evaluation of co-administration with vitamin supplement on the bioavailability Lima, Isabela de Paula doxicilina, comprimidos mastigáveis, palatabilidade, farmacocinética. doxycycline, chewable tablets, palatability, pharmacokinetic. |
title_short |
Development and pharmacokinetic evaluation of chewable doxycycline tablets in Beagle dogs: comparison with a commercial formulation and evaluation of co-administration with vitamin supplement on the bioavailability |
title_full |
Development and pharmacokinetic evaluation of chewable doxycycline tablets in Beagle dogs: comparison with a commercial formulation and evaluation of co-administration with vitamin supplement on the bioavailability |
title_fullStr |
Development and pharmacokinetic evaluation of chewable doxycycline tablets in Beagle dogs: comparison with a commercial formulation and evaluation of co-administration with vitamin supplement on the bioavailability |
title_full_unstemmed |
Development and pharmacokinetic evaluation of chewable doxycycline tablets in Beagle dogs: comparison with a commercial formulation and evaluation of co-administration with vitamin supplement on the bioavailability |
title_sort |
Development and pharmacokinetic evaluation of chewable doxycycline tablets in Beagle dogs: comparison with a commercial formulation and evaluation of co-administration with vitamin supplement on the bioavailability |
author |
Lima, Isabela de Paula |
author_facet |
Lima, Isabela de Paula Magalhães, Viviane de Souza de Oliveira, Rodrigo Machado Ferreira, Thais Paes dos Santos, Gabriela Carmelinda Martins Alves, Melina Cardilo Campos Pereira, Geraldo Augusto da Silva, Fernanda Cristina Santos Rodrigues, Liliane Ferreira Borges, Debora Azevedo de Oliveira, Priscila Cardim Scott, Fabio Barbour Cid, Yara `Peluso |
author_role |
author |
author2 |
Magalhães, Viviane de Souza de Oliveira, Rodrigo Machado Ferreira, Thais Paes dos Santos, Gabriela Carmelinda Martins Alves, Melina Cardilo Campos Pereira, Geraldo Augusto da Silva, Fernanda Cristina Santos Rodrigues, Liliane Ferreira Borges, Debora Azevedo de Oliveira, Priscila Cardim Scott, Fabio Barbour Cid, Yara `Peluso |
author2_role |
author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Lima, Isabela de Paula Magalhães, Viviane de Souza de Oliveira, Rodrigo Machado Ferreira, Thais Paes dos Santos, Gabriela Carmelinda Martins Alves, Melina Cardilo Campos Pereira, Geraldo Augusto da Silva, Fernanda Cristina Santos Rodrigues, Liliane Ferreira Borges, Debora Azevedo de Oliveira, Priscila Cardim Scott, Fabio Barbour Cid, Yara `Peluso |
dc.subject.por.fl_str_mv |
doxicilina, comprimidos mastigáveis, palatabilidade, farmacocinética. doxycycline, chewable tablets, palatability, pharmacokinetic. |
topic |
doxicilina, comprimidos mastigáveis, palatabilidade, farmacocinética. doxycycline, chewable tablets, palatability, pharmacokinetic. |
description |
Doxycycline (DOX) is the antibiotic of choice for the treatment of canine monocytic ehrlichiosis (CME), one of the main infectious diseases affecting dogs. Despite the therapeutic simplicity, the need for long-term use of DOX tablets (28 days) and gastrointestinal effects may pose problems. The aim of the study was to develop a DOX chewable tablet, evaluate its palatability and pharmacokinetic profile in comparison with a commercial formulation, Doxifin®, and evaluate the influence of co-administration with vitamin supplement on the bioavailability of doxycycline. The AUC0-t values found for DOX chewable tablets (13.85 ± 3.81 μg.h/mL) and Doxifin® (15.88 ± 4.38 μg.h/mL) did not differ significantly (p<0.05). The co-administration of the vitamin supplement Hemolitan® influenced the pharmacokinetic profile of DOX, leading to a decrease in bioavailability for chewable DOX tablets and Doxifin®, with relative bioavailability values (F) of 64% and 62%, respectively. Palatability evaluations confirmed the palatability of the chewable tablets. Therefore, a DOX chewable tablet is an important alternative that can overcome some of the challenges associated with the characteristic bitter taste of doxycycline, with considerable reduction animal stress, and with plasma doxycycline concentrations equivalent in practical terms to a conventional product. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-09-28 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion peer reviewed Avaliado pelos pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rbmv.org/BJVM/article/view/1194 10.29374/2527-2179.bjvm002921 |
url |
https://rbmv.org/BJVM/article/view/1194 |
identifier_str_mv |
10.29374/2527-2179.bjvm002921 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://rbmv.org/BJVM/article/view/1194/1096 https://rbmv.org/BJVM/article/view/1194/1216 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf text/xml |
dc.publisher.none.fl_str_mv |
Sociedade de Medicina Veterinária do Estado do Rio de Janeiro. |
publisher.none.fl_str_mv |
Sociedade de Medicina Veterinária do Estado do Rio de Janeiro. |
dc.source.none.fl_str_mv |
Brazilian Journal of Veterinary Medicine; Vol. 43 No. 1 (2021); e002921 Revista Brasileira de Medicina Veterinária; v. 43 n. 1 (2021); e002921 2527-2179 0100-2430 reponame:Brazilian Journal of Veterinary Medicine instname:Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ) instacron:SBMV |
instname_str |
Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ) |
instacron_str |
SBMV |
institution |
SBMV |
reponame_str |
Brazilian Journal of Veterinary Medicine |
collection |
Brazilian Journal of Veterinary Medicine |
repository.name.fl_str_mv |
Brazilian Journal of Veterinary Medicine - Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ) |
repository.mail.fl_str_mv |
contato.rbmv@gmail.com |
_version_ |
1798313111627759616 |